68Ga-Pentixafor PET/CT for Imaging of Chemokine Receptor 4 Expression in Waldenstrom Macroglobulinemia/Lymphoplasmacytic Lymphoma: Comparison to 18F-FDG PET/CT

Conclusion: 68Ga-pentixafor might be a promising imaging agent for the assessment of WM/LPL.
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Clinical Source Type: research

Related Links:

Publication date: Available online 14 January 2020Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Yenny Alejandra Moreno Vanegas, Ridas Juskevicius, Bhagirathbhai Dholaria
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Lymphoplasmacytic lymphoma (LPL) with or without Waldenstr ӧm macroglobulinemia (WM) is a rare lymphoproliferative disorder (LPD) characterized by the presence of monoclonal immunoglobulin M (IgM) paraproteinemia and bone marrow (BM) infiltration by small lymphocytes with plasmacytoid or plasma cell differentiation.1 LPL/WM constitutes less than 5% of all non-Hodgkin lymphomas (NHLs) and 1-2% of hematological malignancies.2 Patients with LPL/WM may be initially asymptomatic (smoldering WM) but over the course of their disease they may present with fatigue, shortness of breath, anemia, lymphadenopathy (LAD), splenomegaly a...
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Case Report Source Type: research
Publication date: Available online 21 November 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Mariana Koehler, Filipa Moita, José Cabeçadas, Maria Gomes da Silva
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Bruton ’s tyrosine kinase (BTK) plays a pivotal role in B-cell proliferation and survival of leukemic cells. Ibrutinib, a molecule targeting BTK, was approved by the United States Food and Drug Administration in 2013 for treatment of mantle cell lymphoma and has since been approved for treatment of sever al other hematologic malignancies, including chronic lymphocytic leukemia (CLL), Waldenström macroglobulinemia, and marginal zone lymphoma (MZL).1 Recently, ibrutinib plus venetoclax have been found to be effective as first-line treatment for high-risk and older patients with CLL.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Case Report Source Type: research
Bruton ’s tyrosine kinase (BTK) plays a pivotal role in B-cell proliferation and survival of leukemic cells. Ibrutinib, a molecule targeting BTK, was approved by the U.S. Food and Drug Administration in 2013 for treatment of mantle cell lymphoma and has since been approved for treatment of several other hematologic malignancies, including chronic lymphocytic leukemia (CLL), Waldenström macroglobulinemia, and marginal zone lymphoma (MZL) (1). Recently, Ibrutinib plus venetoclax have been found to be effective as first line treatment for high risk and older patients with CLL (2).
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Case Report Source Type: research
Clinical, Laboratory, and Bone Marrow Findings of 31 Patients With Waldenström Macroglobulinemia. Ann Lab Med. 2020 May;40(3):193-200 Authors: Ahn A, Park CJ, Cho YU, Jang S, Seo EJ, Lee JH, Yoon DH, Suh C Abstract BACKGROUND: Waldenström macroglobulinemia (WM) is a subset of lymphoplasmacytic lymphoma (LPL) with bone marrow (BM) involvement and an IgM monoclonal gammopathy of any level. We aimed to identify the clinical, laboratory, and BM findings of patients with WM and to evaluate the usefulness of CD154 for the diagnosis and prognosis of WM. METHODS: We reviewed the medical records a...
Source: Annals of Laboratory Medicine - Category: Laboratory Medicine Tags: Ann Lab Med Source Type: research
We describe the case of a 49 year old woman with leptomeningeal LPL who did not fulfil diagnostic criteria for concomitant systemic WM at presentation, and who failed to respond to conventional chemotherapy treatment (including high dose methotrexate) but did respond to the oral Bruton tyrosine kinase (BTK) inhibitor ibrutinib. This highlights an important variation in the typical natural history of this rare disease and also further supplements emerging evidence regarding efficacy of ibrutinib in its treatment.
Source: Journal of Clinical Neuroscience - Category: Neuroscience Source Type: research
Publication date: Available online 21 November 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Mariana Koehler, Filipa Moita, José Cabeçadas, Maria Gomes da Silva
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Waldenstr öm macroglobulinemia (WM) is an uncommon indolent B-cell lymphoma characterized by the presence of an immunoglobulin (Ig) M monoclonal gammopathy in association with lymphoplasmacytic lymphoma (LPL) in the bone marrow (BM).1
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Case Report Source Type: research
Waldenstrom ’s Macroglobulinemia (WM) is an uncommon indolent B cell lymphoma characterized by the presence of an IgM monoclonal gammopathy in association with lymphoplasmacytic lymphoma (LPL) in the bone marrow1 .
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Case Report Source Type: research
More News: CT Scan | Liver | Lymphoma | Macroglobulinemia | Nuclear Medicine | PET Scan | Statistics | Study | Urology & Nephrology | Waldenstrom's Macroglobulinemia